A Randomized, Double-blind, Multi-center Phase III Clinical Study to Assess the Efficacy and Safety of Sulfatinib Compared to Placebo in Patients With Advanced Pancreatic Neuroendocrine Tumors

Trial Profile

A Randomized, Double-blind, Multi-center Phase III Clinical Study to Assess the Efficacy and Safety of Sulfatinib Compared to Placebo in Patients With Advanced Pancreatic Neuroendocrine Tumors

Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Sulfatinib (Primary)
  • Indications Neuroendocrine tumours; Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms SANET-p
  • Sponsors Hutchison MediPharma
  • Most Recent Events

    • 02 Aug 2016 According to a Chi-Med media release, company expects to complete enrollment in H2 2017 and publish top-line results in 2018.
    • 21 Mar 2016 According to a Chi-Med media release, first patient in this trial was dosed on March 18, 2016. Top-line results from this trial are expected in 2018.
    • 18 Dec 2015 Top-line results from this trial are expected in 2017, according to a Chi-Med media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top